Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor

A multi-institutional study was conducted and published results showing how paclitaxel-based treatments may offer real promise for children with recurrent or treatment -resistant Wilms tumor.  In this study, nearly 60% of patients experienced tumor shrinkage or disease stabilization- a meaningful advancement.  Based on this study, the Children’s Oncology Group is planning to study paclitaxel prospectively in patients with high-risk recurrent Wilms tumor.  The paper from this study can be found here with acknowledgements to Alex’s Army at the end.